Metabolic pathways and chemotherapy resistance in acute myeloid leukemia (AML): Insights into Enoyl-CoA hydratase domain-containing protein 3 (ECHDC3) as a potential therapeutic target
<i>ECHDC3</i> contributes to chemotherapy resistance in AML by regulating mitochondrial function, autophagy, and metabolic pathways. This study highlights <i>ECHDC3</i> as a potential therapeutic target and offers insights into the development of AML treatments to overcome drug resistance.
Authors
- Hanfei Guo (ORCID: https://orcid.org/0000-0001-5897-3145)
- Liting Niu
- Jinfang Zhao
- Yijing Zhao (ORCID: https://orcid.org/0009-0009-7531-1528)
Institutions
- Jilin University (CN)
- Peking University (CN)
- VA Palo Alto Health Care System (US)
- Peking University People's Hospital (CN)
- First Hospital of Jilin University (CN)
- Stanford University (US)
Publication Details
- Journal
- Cancer Pathogenesis and Therapy
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1016/j.cpt.2025.08.002
- Primary Topic
- Metabolomics and Mass Spectrometry Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00